/-/media/corpsite/assets/hkstp-logo/hkstp_logo_25_v2_white_0810v2.svg?mw=1980&rev=2a340e7fbf814bbbab9ab7fe854878c7&hash=3E4F85D867EE687322D4B7496A0A452D
Forward Pharmaceuticals Hong Kong Company Limited084e916e-223e-f111-88b4-6045bd1d6635_CompanyLogo_18092026
Biomedical Technology

Forward Pharmaceuticals (Hong Kong) Company Limited

Company

Description

Forward Pharmaceuticals (Hong Kong) Co., Ltd. serves as a key platform for the internationalisation strategy of Forward Pharma Group. It is primarily responsible for the Group’s business development.

Our Beliefs

Based in China with a global vision, we are dedicated to filling international gaps and developing "global-first" innovative drugs to better serve patients worldwide

Product

FWD1802: A third-generation oral selective estrogen receptor degrader (SERD) for the treatment of ER+/HER2- breast cancer. It possesses dual mechanisms of ER degradation and antagonism, and can overcome resistance to current endocrine therapies. The drug received Phase 1 clinical trial approval from China's National Medical Products Administration (NMPA) in 2023 and is expected to be launched in 2028.

Explore other companies

directory-icon
Biomedical Technology
Xellera Therapeutics Asia Limited
Grid Biosciences Hong Kong Limitednew company logo
Biomedical Technology
Grid Biosciences Hong Kong Limited
directory-icon
Biomedical Technology
AusMed Global Limited
Life Code LimitedProfilePic76439
Biomedical Technology
Life Code Limited
Hong Kong Science & Technology Parks Corporation - Company Directory - Forward Pharmaceuticals (Hong Kong) Company Limited
Company Directory